Skip to main content
OpenTrials
Completed

NCT Number: NCT01794351

Cognitive Effects of 500mg Trans-resveratrol

This study investigated the potentially cognitive enhancing effects of 500mg trans-resveratrol in healthy, young humans.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive Performance Mood

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brain performance and nutrition research centre, Northumbria university

Newcastle upon Tyne, Tyne and Wear, NE1 8ST, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-35yrs, healthy.

Exclusion criteria

  • Drug/alcohol abuse, taking prescription medication (apart from contraception) or herbal supplements, having food intolerances or allergies, having suffered a head-injury or neurological/neuro-developmental disorder, uncorrected sight problems, pregnant or seeking to become so, excessive caffeine use (e.g. more than 6 cups of coffee per day).

Treatment and study plan

Trans-resveratrol

Dietary Supplement

In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.

Placebo

Other

In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.

Other names: Pharmaceutical grade silica

Primary outcomes

  1. Number of participants with altered cognitive function at 40mins post-dose

    Time frame: 40mins Post-dose

    This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from the baseline to 40min post-dose scores.

  2. Number of participants with altered cognitive function at 2.5hrs post-dose

    Time frame: 2.5hrs post-dose

    This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 2.5hr post-dose scores.

  3. Number of participants with altered cognitive function at 4hrs post-dose

    Time frame: 4hrs post-dose

    This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 4hr post-dose scores.

  4. Number of participants with altered cognitive function at 6hrs post-dose

    Time frame: 6hrs post-dose

    This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 6hr post-dose scores.

Secondary outcomes

  1. Number of participants with altered mood at 40mins post-dose.

    Time frame: 40mins post-dose

    This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 40mins post-dose scores.

  2. Number of participants with altered mood at 2.5hrs post-dose

    Time frame: 2.5hrs post-dose

    This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 2.5hrs post-dose scores.

  3. Number of participants with altered mood at 4hrs post-dose

    Time frame: 4hrs pos-dose

    This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 4hrs post-dose scores.

  4. Number of participants with altered mood at 6hrs post-dose

    Time frame: 6hrs post-dose

    This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 6hrs post-dose scores.

Sponsors and collaborators

Lead sponsor

Northumbria University

Other

Registry information

Official study title

Effects of Trans-resveratrol on Cognitive Performance in Healthy, Young Humans: a Double-blind, Placebo-controlled, Crossover Investigation.

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Feb 18, 2013
Registry last updated
Feb 18, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.